Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
P/E ratio for Pharvaris N.V. (PHVS)
P/E ratio as of 2023: -9.66
According to Pharvaris N.V.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -9.66. At the end of 2022 the company had a P/E ratio of -4.62.
P/E ratio history for Pharvaris N.V. from 2017 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -9.66 |
| 2022 | -4.62 |
| 2021 | -9.01 |
| 2020 | -27.87 |
| 2019 | -15.59 |
| 2018 | -186.63 |
| 2017 | 0.00 |